

**NCI Clinical Trials and Translational Research Advisory Committee**  
***Ad hoc* Working Group on Glioblastoma**

**Mission Statement**

The National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) *ad hoc* Translational Research Strategy Subcommittee (TRSS) will convene an *ad hoc* Working Group on Glioblastoma to survey the scientific horizons broadly to:

1. Help identify the most provocative and impactful translational research questions to advance the diagnosis and treatment of glioblastoma;
2. Examine and identify the most important opportunities for application of new technologies to glioblastoma translational research;
3. Identify glioblastoma translational research knowledge gaps.

Working Group membership will include select CTAC, National Cancer Advisory Board (NCAB), and NCI Board of Scientific Advisors (BSA) members, as well as individuals with expertise in clinical and basic research, patient care, advocacy, and others with expertise in glioblastoma.

The Working Group will advise the TRSS, CTAC, NCAB, BSA, and the NCI Director.